Pages that link to "Q35203637"

The following pages link to Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. (Q35203637):

Displaying 39 items.

• The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma (Q27853383) (← links)
• Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer (Q28067777) (← links)
• The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation (Q30534479) (← links)
• Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells (Q33604480) (← links)
• Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met (Q33702320) (← links)
• Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment (Q33794185) (← links)
• Development and strategies of VEGFR-2/KDR inhibitors (Q34436101) (← links)
• Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer. (Q34640075) (← links)
• Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study (Q35487148) (← links)
• The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis (Q35646553) (← links)
• A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth (Q35952832) (← links)
• MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction (Q36520263) (← links)
• c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations (Q36544653) (← links)
• Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. (Q36809577) (← links)
• Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets (Q37406889) (← links)
• c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma (Q37472110) (← links)
• INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models (Q37502372) (← links)
• Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies (Q37545045) (← links)
• c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications (Q37651008) (← links)
• Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? (Q37921797) (← links)
• Targeting the Met pathway in lung cancer (Q38002473) (← links)
• Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. (Q38056554) (← links)
• Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer (Q38081379) (← links)
• Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. (Q38093654) (← links)
• Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research (Q38183485) (← links)
• Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance (Q38809675) (← links)
• Anoikis and EMT: Lethal "Liaisons" during Cancer Progression (Q39028687) (← links)
• Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint (Q41923223) (← links)
• Synthesis and antitumor activity of novel 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-oxo-1,4-dihydroquinoline-3-carboxamide moiety (Q46492003) (← links)
• The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study (Q47411655) (← links)
• Herbal formula YGJDSJ inhibits anchorage-independent growth and induces anoikis in hepatocellular carcinoma Bel-7402 cells (Q48233039) (← links)
• Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer (Q51335207) (← links)
• Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines. (Q53688956) (← links)
• Cuprous oxide nanoparticles inhibit angiogenesis via down regulation of VEGFR2 expression. (Q54379435) (← links)
• Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer. (Q55168118) (← links)
• NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR (Q58712169) (← links)
• Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer (Q59792439) (← links)
• UPLC-MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats (Q91789909) (← links)
• Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression (Q92242780) (← links)